Chronic therapy with a partial adenosine a1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure

Circulation: Heart Failure

Volumn 6, Issue 3, 2013, Pages 563-571

  Sabbah, Hani N ^a   Gupta, Ramesh C ^a   Kohli, Smita ^a   Wang, Mengjun ^a   Rastogi, Sharad ^a   Zhang, Kefei ^a   Zimmermann, Katja ^b   Diedrichs, Nicole ^b   Albrecht Küpper, Barbara E ^b  

^a HENRY FORD HOSPITAL   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

Adenosine receptors; Heart failure; Protein expression; Ventricular remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CAPADENOSON; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; NORADRENALIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FIBROSING ALVEOLITIS; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE RECEPTORS; HEART FAILURE; PROTEIN EXPRESSION; VENTRICULAR REMODELING;

ADENOSINE A1 RECEPTOR AGONISTS; AMINOPYRIDINES; ANIMALS; DOGS; ECHOCARDIOGRAPHY, DOPPLER; HEART FAILURE; HEMODYNAMICS; STROKE VOLUME; THIAZOLES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 84879205967     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.000208     Document Type: Article

References (50)

1. Hussain T, Mustafa SJ. Binding of A1 adenosine receptor ligand [3H]8-cyclopentyl-1,3-dipropylxanthine in coronary smooth muscle. Circ Res. 1995;77:194-198.
2. Mustafa SJ, Morrison RR, Teng B, Pelleg A Adenosine receptors and the heart: Role in regulation of coronary blood flow and cardiac electrophysiology Handb Exp Pharmacol. 2009;163:161-188.
3. Musser B, Morgan ME, Leid M, Murray TF, Linden J, Vestal RE Species comparison of adenosine and beta-adrenoceptors in mammalian atrial and ventricular myocardium Eur J Pharmacol 1993;246:105-111.
4. Nell PG, Albrecht-Küpper B. The adenosine A1 receptor and its ligands. Prog Med Chem. 2009;47:163-201.
5. Albrecht-Küpper BE, Leineweber K, Nell PG. Partial adenosine A1 receptor agonists for cardiovascular therapies. Purinergic Signal. 2012;8(suppl 1):91-99.
6. Ellenbogen KA, O'Neill G, Prystowsky EN, Camm JA, Meng L, Lieu HD, Jerling M, Shreeniwas R, Belardinelli L, Wolff AA; TEMPEST Study Group Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson Circulation. 2005;111:3202-3208.
7. Peterman C, Sanoski CA. Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol Rev. 2005;13:315-321
8. Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol. 2009; 193:25-58.
9. Tendera M, Gaszewska-urek E, Parma Z, Ponikowski P, Jankowska E, Kawecka-Jaszcz K, Czarnecka D, Krzemiska-Pakua M, Bednarkiewicz Z, Sosnowski M, Ochan Kilama M, Agrawal R. The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clin Res Cardiol. 2012;101:585-591.
10. Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, Hawkins ET, Goldstein S Am J Physiol. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations 1991;260(4 Pt 2):H1379-H1384.
11. Dodge HT, Sandler H, Baxley WA, Hawley RR Am J Cardiol. Usefulness and limitations of radiographic methods for determining left ventricular volume 1966;18:10-24.
12. Sabbah HN, Imai M, Cowart D, Amato A, Carminati P, Gheorghiade M Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure Am J Cardiol. 2007;99(2A):41A-46A.
13. Rastogi S, Guerrero M, Wang M, Ilsar I, Sabbah MS, Gupta RC, Sabbah HN Myocardial transfection with naked DNA plasmid encoding hepatocyte growth factor prevents the progression of heart failure in dogs Am J Physiol Heart Circ Physiol. 2011;300:H1501-H1509.
14. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;99:1926-1935.
15. Sabbah HN, Stanley WC, Sharov VG, Mishima T, Tanimura M, Benedict CR, Hegde S, Goldstein S Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure Circulation. 2000;102:1990-1995.
16. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363:1419-1428.
17. Ely SW, Berne RM Protective effects of adenosine in myocardial ischemia Circulation. 1992;85:893-904.
18. Sommerschild HT, Kirkebøen KA Adenosine and cardioprotection during ischaemia and reperfusion-an overview Acta Anaesthesiol Scand. 2000;44:1038-1055.
19. Olafsson B, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, Virmani R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the noreflow phenomenon. Circulation. 1987;76:1135-1145.
20. Liang B, Stewart D, Jacobson K. Adenosine A1 and A3 receptors: distinct cardioprotection. Drug Dev Res. 2001; 52:366-378.
21. DeWitt DF, Wangler RD, Thompson CI, Sparks HV Jr. Phasic release of adenosine during steady state metabolic stimulation in the isolated guinea pig heart. Circ Res. 1983;53:636-643.
22. Dobson JG Jr. Mechanism of adenosine inhibition of catecholamineinduced responses in heart. Circ Res. 1983;52:151-160.
23. Richardt G, Waas W, Kranzhöfer R, Mayer E, Schömig A. Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia. Circ Res. 1987;61:117-123.
24. Bott-Flügel L, Bernshausen A, Schneider H, Luppa P, Zimmermann K, Albrecht-Küpper B, Kast R, Laugwitz KL, Ehmke H, Knorr A, Seyfarth M. Selective attenuation of norepinephrine release and stressinduced heart rate increase by partial adenosine A1 agonism. PLoS One. 2011;6:e18048.
25. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation. 1994;89:2852-2859.
26. Mauser M, Hoffmeister HM, Nienaber C, Schaper W. Influence of ribose, adenosine, and "AICAR" on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog. Circ Res. 1985;56:220-230.
27. Reibel DK, Rovetto MJ. Myocardial adenosine salvage rates and restoration of ATP content following ischemia. Am J Physiol. 1979;237:H247-H252.
28. Schwabe U, Schönhöfer PS, Ebert R. Facilitation by adenosine of the action of insulin on the accumulation of adenosine 3':5'-monophosphate, lipolysis, and glucose oxidation in isolated fat cells. Eur J Biochem. 1974;46:537-545.
29. Sabbah HN, Sharov V, Riddle JM, Kono T, Lesch M, Goldstein S. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol. 1992;24:1333-1347.
30. Sharov VG, Goussev A, Lesch M, Goldstein S, Sabbah HN. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol. 1998;30:1757-1762.
31. Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN. Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol. 2007;42:150-158.
32. Sharov VG, Todor AV, Silverman N, Goldstein S, Sabbah HN. Abnormal mitochondrial respiration in failed human myocardium. J Mol Cell Cardiol. 2000;32:2361-2367.
33. Laskowski KR, Russell RR III. Uncoupling proteins in heart failure. Curr Heart Fail Rep. 2008;5:75-79.
34. Liu SS. Generating, partitioning, targeting and functioning of superoxide in mitochondria. Biosci Rep. 1997;17:259-272.
35. Noma T, Nishiyama A, Mizushige K, Murakami K, Tsuji T, Kohno M, Rahman M, Fukui T, Abe Y, Kimura S. Possible role of uncoupling protein in regulation of myocardial energy metabolism in aortic regurgitation model rats. FASEB J. 2001;15:1206-1208.
36. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104:2923-2931.
37. Razeghi P, Young ME, Ying J, Depre C, Uray IP, Kolesar J, Shipley GL, Moravec CS, Davies PJ, Frazier OH, Taegtmeyer H. Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology. 2002;97:203-209.
38. Young ME, Patil S, Ying J, Depre C, Ahuja HS, Shipley GL, Stepkowski SM, Davies PJ, Taegtmeyer H. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. FASEB J. 2001;15:833-845.
39. Bugger H, Guzman C, Zechner C, Palmeri M, Russell KS, Russell RR III. Uncoupling protein downregulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation. Cancer Chemother Pharmacol. 2011;67:1381-1388.
40. Bodyak N, Rigor DL, Chen YS, Han Y, Bisping E, Pu WT, Kang PM. Uncoupling protein 2 modulates cell viability in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol. 2007;293:H829-H835.
41. Sack MN. Mitochondrial depolarization and the role of uncoupling proteins in ischemia tolerance. Cardiovasc Res. 2006;72:210-219.
42. Sabbah HN. Apoptotic cell death in heart failure. Cardiovasc Res. 2000;45:704-712.
43. Sharov VG, Sabbah HN, Shimoyama H, Goussev AV, Lesch M, Goldstein S. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol. 1996;148:141-149.
44. Xiang F, Huang YS, Zhang DX, Chu ZG, Zhang JP, Zhang Q. Adenosine A1 receptor activation reduces opening of mitochondrial permeability transition pores in hypoxic cardiomyocytes. Clin Exp Pharmacol Physiol. 2010;37:343-349.
45. Sack MN, Kelly DP. The energy substrate switch during development of heart failure: gene regulatory mechanisms (Review). Int J Mol Med. 1998;1:17-24.
46. Yu G AM, Makkinje A, Yi-Chun L, Tod G. CPT-1 gene expression and fatty acid oxidation are regulated by p38 MAP kinase through MEF2 factors. Circulation. 2000; 102 (II):7-8.
47. Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: a role for interstitial fibrosis. Mol Cell Biochem. 1995;147:29-34.
48. Sabbah HN, Sharov VG, Goldstein S. Cell death, tissue hypoxia and the progression of heart failure. Heart Fail Rev. 2000;5:131-138.
49. Sharov VG, Todor A, Suzuki G, Morita H, Tanhehco EJ, Sabbah HN. Hypoxia, angiotensin-II, and norepinephrine mediated apoptosis is stimulus specific in canine failed cardiomyocytes: a role for p38 MAPK, Fas-L and cyclin D1. Eur J Heart Fail. 2003;5:121-129.
50. Todor A, Sharov VG, Tanhehco EJ, Silverman N, Bernabei A, Sabbah HN. Hypoxia-induced cleavage of caspase-3 and DFF45/ICAD in human failed cardiomyocytes. Am J Physiol Heart Circ Physiol. 2002;283:H990-H995.